¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inhibitor polymerization"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • ionic polymerization
    ÀÌ¿ÂÁßÇÕ
  • instantaneous polymerization
    ¼ø°£ÁßÇÕ
  • mass polymerization
    µ¢ÀÌÁßÇÕ
  • noncatalytic polymerization
    ¹«Ã˸ÅÁßÇÕ
  • photochemical polymerization
    ±¤È­ÇÐÀûÁßÇÕ
  • polymerization
    ÁßÇÕ, ÁßÇÕÀÛ¿ë
  • polymerization promotor
    ÁßÇÕÃËÁøÁ¦
  • reversible polymerization
    µÇÁý±âÁßÇÕ, °¡¿ªÁßÇÕ
  • spray polymerization
    ºÐ¹«ÁßÇÕ
  • suspension polymerization
    ºÎÀ¯ÁßÇÕ
  • vapor phase polymerization
    Áõ±â»óÁßÇÕ
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymerization
    ÁßÇÕ¹ÝÀÀ, ÁßÇÕÀÛ¿ë
  • inhibitor
    ¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • heat of polymerization
    ÁßÇÕ¿­
  • instantaneous polymerization
    ¼ø°£ÁßÇÕ
  • ionic polymerization
    ÀÌ¿ÂÁßÇÕ
  • mass polymerization
    µ¢ÀÌÁßÇÕ
  • noncatalytic polymerization
    ¹«Ã˸ÅÁßÇÕ
  • polymerization
    ÁßÇÕ¹ÝÀÀ, ÁßÇÕÀÛ¿ë
  • photochemical polymerization
    ±¤È­ÇÐÀûÁßÇÕ
  • polymerization promotor
    ÁßÇÕÃËÁøÁ¦
  • reversible polymerization
    µÇÁý±âÁßÇÕ, °¡¿ªÁßÇÕ
  • spray polymerization
    ºÐ¹«ÁßÇÕ
  • suspension polymerization
    ºÎÀ¯ÁßÇÕ
  • vapor phase polymerization
    Áõ±â»óÁßÇÕ
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • addition polymerization
    ºÎ°¡ÁßÇÕ.
  • heat of polymerization
    ÁßÇÕ¿­(ñìùêæð).
  • instantaneous polymerization
    ¼ø°£ÁßÇÕ.
  • photochemical polymerization
    ±¤È­ÇÐÀû ÁßÇÕ(¡­îÜñìùê).
  • polymerization
    ÁßÇÕ(¹ÝÀÀ)(ñìùêÚãëë), ÁßÇÕ(ÀÛ¿ë)(¡­íÂéÄ).
  • polymerization promotor
    ÁßÇÕÃËÁøÁ¦ (¡­õµòäð¥).
  • rate of polymerization
    ÁßÇÕ·ü(ñìùêëÒ).
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • CAI=£¾carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à, ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú.
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • RIMA, see reversible inhibitor of MAO-A
    °¡¿ªÀû ´Ü°¡¾Æ¹Î-A »êÈ­È¿¼Ò¾ïÁ¦Á¦
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • addition polymerization
    ºÎ°¡ÁßÇÕ.
  • emulsion polymerization
    ¿¡¸ÖÁ¯ÁßÇÕ(¡­ñìùê).
  • heat of polymerization
    ÁßÇÕ¿­(ñìùêæð).
  • instantaneous polymerization
    ¼ø°£ÁßÇÕ.
  • ionic polymerization
    ÀÌ¿ÂÁßÇÕ(¡­ñìùê).
  • mass polymerization
    ±«»óÁßÇÕ(ÎÔßÒñìùê).
  • noncatalytic polymerization
    ¹«Ã˸ÅÁßÇÕ(~ñìùê).
  • photochemical polymerization
    ±¤È­ÇÐÀû ÁßÇÕ(¡­îÜñìùê).
  • polymerization
    ÁßÇÕ(¹ÝÀÀ)(ñìùêÚãëë), ÁßÇÕ(ÀÛ¿ë)(¡­íÂéÄ).
  • polymerization promotor
    ÁßÇÕÃËÁøÁ¦ (¡­õµòäð¥).
  • rate of polymerization
    ÁßÇÕ·ü(ñìùêëÒ).
  • reversible polymerization
    °¡¿ªÁßÇÕ(Ê¦æ½ ñìùê).
  • spray polymerization
    ºÐ¹«ÁßÇÕ(ÝÄÙöñìùê).
  • suspension polymerization
    ÇöŹÁßÇÕ(úØöú ñìùê).
  • vapor phase polymerization
    Áõ±â»óÁßÇÕ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polymerization
    "ÁßÇÕ(ñìùê), ÁßÇÕ¹ÝÀÀ(ñìùêÚãëë)"
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • Bowman-Birk inhibitor
    "º¸¿ì¸¸-¹÷Å© ÀúÇØÀÚ(îÁúªí­), º¸¿ì¸¸-¹÷Å© ÀúÇØÁ¦(îÁúªð¥)"
  • competitive inhibitor
    °æÇÕÀúÇØÁ¦(ÌæùêîÁúªð¥)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
  • heme-controlled inhibitor
    Èû-Á¦¾î(ð¤åÙ) ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor
    ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor constant
    ÀúÇØÁ¦»ó¼ö(îÁúªð¥ßÈâ¦)
  • irreversible inhibitor
    ºñ°¡¿ª ÀúÇØÁ¦(ުʦæ½îÁúªð¥)
  • Kunitz inhibitor
    Äï´ÏÃ÷ ÀúÇØÁ¦(îÁúªð­)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • noncompetitive inhibitor
    ºñ°áÇÕ ÀúÇØÁ¦(ު̿ùêîÁúªðº)
  • ovulation inhibitor
    ¹è¶õ ÀúÇØÁ¦(ÛÉÕ°îÁúªð¥)
  • respiratory inhibitor
    È£Èí ÀúÇØÁ¦(îÁúªð¥)
  • reversible inhibitor
    °¡¿ª ÀúÇØÁ¦(îÁúªð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦Á¦, ¾ïÁ¦¹°Áú, ¾ïÁ¦ÀÎÀÚ, ¾ïÁ¦½Å°æ, ¾ïÁ¦À¯ÀüÀÚ, ¾ïÁ¦¾à
  • polymerization
    ÁßÇÕ(¹ÝÀÀ), ÁßÇÕ(ÀÛ¿ë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DP data processing; deep pulse; definitive procedure; degradation product; degree of polymerization; de...
BPTI basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in...
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
ESI elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection
PTI pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACE inhibitor angiotensin converting enzyme inhibitor
CPI 1-cysteine proteinase inhibitor
PIC 1-plasmin inhibitor complex
PAI-1 Plaminogen Activator Inhibitor-1
PI 1-protease inhibitor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • polymerization inhibitor
    ÁßÇÕ ±ÝÁöÁ¦
    ÁßÇÕ ¹ÝÀÀÀ» ¹æÇØÇϱ⵵ Çϰí, ÁßÁöÇÒ ¼ö ÀÖ´Â ¹°Áú.
  • addition polymerization
    ÷°¡ ÁßÇÕ, ºÎ°¡ ÁßÇÕ
    ÀÌÁß °áÇÕÀ» °¡Áø ´Ü·®Ã¼°¡ ´Ù¸¥ ´Ü·®Ã¼¿Í °áÇÕÇÏ¿© °Å´ë È­ÇÕ¹°À» Çü¼ºÇÏ´Â ÁßÇÕ¹ÝÀÀÀ¸·Î ºÎ»ê¹°ÀÌ Çü¼ºµÇÁö ¾Ê´Â´Ù.
  • condensation polymerization
    Ãà ÁßÇÕ
    2°³ ÀÌ»óÀÇ ºÐÀÚ ¶Ç´Â ±× ÀÌ»óÀÇ ´Ü¼øÇÑ ºÐÀÚ°£¿¡¼­ º¼ ¼ö ÀÖ´Â ºñ½ÁÇÑ È­ÇйÝÀÀ°ú °°ÀÌ µ¿ÀÏÇÑ ±â´É¿¡ ÀÇÇÏ¿© ÁøÇàµÇ´Â ÁßÇÕ ¹ÝÀÀÀÌ´Ù. ´ÜÇÕü´Â ¹°°ú ¾Ï¸ð´Ï¾Æ°°Àº ºÎ»ê¹°À» »ý¼ºÇϸ鼭 ¹ÝÀÀÇÑ´Ù.
  • cross polymerization
    ±³Â÷ ÁßÇÕ
    ¼±»ó ÁßÇÕü ºÐÀÚ »çÀÌÀÇ È­ÇÐ °áÇÕ Çü¼ºÀº ±× ºÐÀÚµé·Î½á µÈ ¹«ÇÑ´ëÀÇ »ïÂ÷¿øÀû ¸Á»ó ±¸Á¶¿¡±îÁö À̸¦ ¼ö ÀÖ´Â ÁßÇÕ ¹ÝÀÀÀÌ´Ù. ±×·¡¼­ Àç·áÀÇ ¿ëÇØµµ, °­µµ, Èí¼ö¼ºÀ» ¹Ù²Ù´Â ÀÔüÀûÀÎ ¸Á»ó ±¸Á¶¸¦ Çü¼ºÇÏ°Ô µÈ´Ù.
  • polymerization
    ÁßÇÕ
    1. ÀÛÀº ºÐÀÚ·®ÀÇ ºÐÀÚµéÀÌ °áÇÕÇØ º¸´Ù Å« ºÐÀÚ·®ÀÇ È­ÇÕ¹°À» Çü¼º. 2. ÀúºÐÀÚ È­ÇÕ¹°¿¡¼­ °íºÐÀÚ È­ÇÕ¹°À» »ý¼ºÇÏ´Â ¹ÝÀÀ.
  • polymerization of acrylic resin
    ¾ÆÅ©¸¯ ¼öÁö ÁßÇÕ¹ý
  • polymerization shrinkage
    ÁßÇÕ ¼öÃà
  • radical polymerization
    ¶óµðÄ® ÁßÇÕ
    À¯¸®±â°¡ ´Ü·®Ã¼¸¦ Ȱ¼ºÈ­Çϰí, ¿¬¼â ¹ÝÀÀÀ» ÀÏÀ¸ÄÑ °íºÐÀÚ¸¦ »ý¼ºÇÏ´Â ¹ÝÀÀ.
  • rate of polymerization
    ÁßÇÕ·ü
  • spray polymerization
    ºÐ¹« ÁßÇÕ
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ ÀÀ°í °áÇÕü
  • C1-esterase inhibitor
    C1-esterase ¾ïÁ¦ ¹°Áú
  • cell wall inhibitor
    ¼¼Æ÷ º® ÇÕ¼º ¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°í ÀÎÀÚ ¾ïÁ¦Á¦
  • collagenase inhibitor
    Äݶó°Ô³ªÁ¦ ¾ïÁ¦ ¹°Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
polymerization <chemistry> The act or process of changing to a polymeric form; the condition resulting from such change.
Source: Websters Dictionary
(01 Mar 1998)
a1-trypsin inhibitor A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin.
Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor.
(05 Mar 2000)
ACE inhibitor <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure.
Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes.
Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril.
(12 Mar 1998)
aldose reductase inhibitor <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes.
Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy.
Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes.
(09 Oct 1997)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
aromatase inhibitor Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens.
(05 Mar 2000)
beta-lactamase inhibitor <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance.
(05 Mar 2000)
Bowman-Birk inhibitor A polypeptide that will inhibit both trypsin and chymotrypsin.
(05 Mar 2000)
C1 esterase inhibitor An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema.
(05 Mar 2000)
carbonate dehydratase inhibitor An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues.
See: acetazolamide, dichlorphenamide.
Synonym: carbonic anhydrase inhibitor.
(05 Mar 2000)
carbonic acid inhibitor <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma.
(27 Sep 1997)
carbonic anhydrase inhibitor <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma.
Examples include acetazolamide, dichlorphenamide and methazolamide.
(27 Sep 1997)
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
glucosidase inhibitor Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦ÀÚ(¹°);¹ÝÀÀ¾ïÁ¦Á¦
  • polymerization
    ÁßÇÕ(¹ÝÀÀ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á